Durability of platelet inhibition by clopidogrel

      We studied the durability of platelet inhibition from combination aspirin and clopidogrel therapy over a 30-day period in patients who underwent elective coronary stenting.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gurbel P.A.
        • Serebruany V.L.
        • Shustov A.R.
        • Bahr R.D.
        • Carpo C.
        • Ohman E.M.
        • Topol E.J., for the
        • GUSTO III Investigators
        Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment.
        J Am Coll Cardiol. 1998; 31: 1466-1473
        • Ruggeri Z.M.
        New insights into the mechanisms of platelet adhesion and aggregation.
        Semin Hematol. 1994; 31: 29-39
        • Gurbel P.A.
        • Kereiakes D.J.
        • Dalesandro M.R.
        • Bahr R.D.
        • O’Connor C.M.
        • Serebruany V.L.
        Role of soluble and platelet-bound p-selectin in discriminating cardiac from non-cardiac chest pain at presentation in the emergency department.
        Am Heart J. 2000; 139: 320-328
        • CAPRIE Steering Committee
        A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
      1. Gurbel PA, Cummings CC, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145:239–247

        • Lau W.C.
        • Waskell L.A.
        • Watkins P.B.
        • Neer C.J.
        • Horowitz K.
        • Hopp A.S.
        • Tait A.R.
        • Carville D.G.M.
        • Guyer K.E.
        • Bates E.R.
        Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation.
        Circulation. 2003; 107: 32-37